Microbiota Transplant Therapy for Pulmonary Arterial Hypertension: Early Safety and Feasibility Study
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This pilot clinical trial will evaluate the initial safety and feasibility of intestinal
microbiota transplantation (IMT) in patients with pulmonary arterial hypertension (PAH). This
trial will inform development of future trials in treatment of PAH. Active drug in capsule
form composed of freeze-dried, encapsulated intestinal microbiota from healthy donors will be
administered to patients with PAH. This study will also allow for limited evaluation of
pharmacokinetics in terms of donor microbiota engraftment and pharmacodynamics in terms of
potential mechanisms. It will also allow for limited evaluation of cardiac endurance and
function prior to and after IMT.